These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

685 related items for PubMed ID: 16435400

  • 1. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 2. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
    Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G, Mudde GC.
    Cancer Res; 2005 Sep 01; 65(17):7934-41. PubMed ID: 16140965
    [Abstract] [Full Text] [Related]

  • 3. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 01; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 4. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 5. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 6. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
    Barbin K, Stieglmaier J, Saul D, Stieglmaier K, Stockmeyer B, Pfeiffer M, Lang P, Fey GH.
    J Immunother; 2006 Aug 20; 29(2):122-33. PubMed ID: 16531813
    [Abstract] [Full Text] [Related]

  • 7. Reduction of N-linked xylose and fucose by expression of rat beta1,4-N-acetylglucosaminyltransferase III in tobacco BY-2 cells depends on Golgi enzyme localization domain and genetic elements used for expression.
    Karg SR, Frey AD, Kallio PT.
    J Biotechnol; 2010 Mar 20; 146(1-2):54-65. PubMed ID: 20083147
    [Abstract] [Full Text] [Related]

  • 8. N-Glycosylation engineering of lepidopteran insect cells by the introduction of the beta1,4-N-acetylglucosaminyltransferase III gene.
    Okada T, Ihara H, Ito R, Nakano M, Matsumoto K, Yamaguchi Y, Taniguchi N, Ikeda Y.
    Glycobiology; 2010 Sep 20; 20(9):1147-59. PubMed ID: 20554946
    [Abstract] [Full Text] [Related]

  • 9. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function.
    Popp O, Moser S, Zielonka J, Rüger P, Hansen S, Plöttner O.
    MAbs; 2018 Sep 20; 10(2):290-303. PubMed ID: 29173063
    [Abstract] [Full Text] [Related]

  • 10. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 11. Expression of rat beta(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum remodels the plant-specific N-glycosylation.
    Frey AD, Karg SR, Kallio PT.
    Plant Biotechnol J; 2009 Jan 30; 7(1):33-48. PubMed ID: 18778316
    [Abstract] [Full Text] [Related]

  • 12. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
    Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G, Kircheis R.
    Mol Immunol; 2007 Mar 30; 44(7):1815-7. PubMed ID: 17011625
    [Abstract] [Full Text] [Related]

  • 13. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M.
    Biotechnol Bioeng; 2004 Sep 05; 87(5):614-22. PubMed ID: 15352059
    [Abstract] [Full Text] [Related]

  • 14. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
    Wright A, Morrison SL.
    J Immunol; 1998 Apr 01; 160(7):3393-402. PubMed ID: 9531299
    [Abstract] [Full Text] [Related]

  • 15. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
    Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, Wakitani M, Ohta S, Satoh M, Shitara K, Niwa R.
    Cancer Res; 2008 May 15; 68(10):3863-72. PubMed ID: 18483271
    [Abstract] [Full Text] [Related]

  • 16. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):93-103. PubMed ID: 16236307
    [Abstract] [Full Text] [Related]

  • 17. Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I.
    Zhong X, Cooley C, Seth N, Juo ZS, Presman E, Resendes N, Kumar R, Allen M, Mosyak L, Stahl M, Somers W, Kriz R.
    Biotechnol Bioeng; 2012 Jul 30; 109(7):1723-34. PubMed ID: 22252477
    [Abstract] [Full Text] [Related]

  • 18. Synthesis of bisected glycoforms of recombinant IFN-beta by overexpression of beta-1,4-N-acetylglucosaminyltransferase III in Chinese hamster ovary cells.
    Sburlati AR, Umaña P, Prati EG, Bailey JE.
    Biotechnol Prog; 1998 Jul 30; 14(2):189-92. PubMed ID: 9548768
    [Abstract] [Full Text] [Related]

  • 19. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Biochem; 2006 Sep 30; 140(3):359-68. PubMed ID: 16861252
    [Abstract] [Full Text] [Related]

  • 20. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb 30; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.